Tam L S, Li E K, Lam C W, Tomlinson B
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, tamls
Lupus. 2000;9(6):413-6. doi: 10.1191/096120300678828541.
To investigate the effects of hydroxychloroquine (HCQ) in Chinese patients with systemic lupus erythematosus who were either on a low dose of prednisone or not on prednisone.
65 consecutive Chinese lupus patients without features of nephritis underwent assessment of the fasting serum lipid profile, including total cholesterol (TC), triglycerides (TG), HDL-cholesteorl (HDL-C), LDL-cholesterol (LDL-C), apolipoprotein A-1 (apo A-1), apolipoprotein B (apo B) and lipoprotein (a) (Lp(a)).
44/65 (67.7%) patients were on HCQ with a dose of 244 +/- 86 mg daily and 34/65 (52.3%) patients were on 4.3 +/- 2.6 mg daily of prednisone. The percentages of patients taking prednisone and the mean dose in those patients receiving this treatment were not different between the groups with or without HCQ treatment. TG tended to be lower in those patients on HCQ (median and interquartile range) (1.0 (0.7-1.4) mmol/L vs 1.2 (0.8 1.6) mmol/L), but there were no significant differences in TC or other lipid parameters including Lp(a) between the 2 groups of patients with or without HCQ treatment.
HCQ had no significant effect on the serum lipid profile in these lupus patients with mild or inactive disease. This finding probably reflects the low doses of corticosteroid used and a lower background lipid level in this population.
研究羟氯喹(HCQ)对中国系统性红斑狼疮患者的影响,这些患者要么正在接受低剂量泼尼松治疗,要么未接受泼尼松治疗。
65例无肾炎特征的中国狼疮患者连续接受空腹血脂谱评估,包括总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、载脂蛋白A-1(apo A-1)、载脂蛋白B(apo B)和脂蛋白(a)(Lp(a))。
44/65(67.7%)例患者服用HCQ,每日剂量为244±86mg,34/65(52.3%)例患者每日服用4.3±2.6mg泼尼松。服用泼尼松的患者百分比及接受该治疗患者的平均剂量在接受或未接受HCQ治疗的组间无差异。服用HCQ的患者TG往往较低(中位数和四分位间距)(1.0(0.7 - 1.4)mmol/L对1.2(0.8 - 1.6)mmol/L),但在接受或未接受HCQ治疗的两组患者中,TC或其他脂质参数包括Lp(a)均无显著差异。
HCQ对这些轻度或非活动性疾病的狼疮患者的血脂谱无显著影响。这一发现可能反映了该人群使用的皮质类固醇剂量较低且基础血脂水平较低。